EGFR and osteosarcoma: Although gefitinib and BIBW2992, two EGFR inhibitors, were reported not effective against osteosarcoma cells [14], we found in this study that ZD6474 exerts a direct anti-osteosarcoma effect in a dose-dependent manner (Figure 1 and Figure 6).